Bicycle Therapeutics (NASDAQ:BCYC) Raised to Strong-Buy at Jefferies Financial Group

Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by stock analysts at Jefferies Financial Group to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

Other research analysts have also issued research reports about the company. Royal Bank Of Canada reissued a “sector perform” rating and set a $11.00 price objective (down previously from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. Truist Financial initiated coverage on Bicycle Therapeutics in a research report on Monday, November 24th. They set a “hold” rating and a $10.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Citizens Jmp set a $12.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Finally, Citigroup reaffirmed an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $21.11.

Bicycle Therapeutics Trading Down 0.2%

Shares of NASDAQ:BCYC opened at $5.23 on Tuesday. The stock has a market capitalization of $362.81 million, a PE ratio of -1.44 and a beta of 1.63. Bicycle Therapeutics has a 1 year low of $5.03 and a 1 year high of $13.11. The firm has a fifty day moving average price of $6.56 and a 200 day moving average price of $7.08.

Insider Buying and Selling at Bicycle Therapeutics

In related news, CFO Alethia Young sold 4,334 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total transaction of $28,127.66. Following the completion of the transaction, the chief financial officer directly owned 87,081 shares in the company, valued at $565,155.69. This represents a 4.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin Lee sold 10,989 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.46, for a total transaction of $70,988.94. Following the completion of the sale, the chief executive officer directly owned 618,996 shares of the company’s stock, valued at approximately $3,998,714.16. This trade represents a 1.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 38,029 shares of company stock worth $251,966. 8.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. GSK plc acquired a new position in shares of Bicycle Therapeutics during the fourth quarter valued at $10,829,000. Schroder Investment Management Group acquired a new position in Bicycle Therapeutics in the fourth quarter valued at about $3,976,000. Acadian Asset Management LLC increased its stake in Bicycle Therapeutics by 454.1% during the 2nd quarter. Acadian Asset Management LLC now owns 698,501 shares of the company’s stock worth $4,840,000 after purchasing an additional 572,439 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Bicycle Therapeutics by 64.7% in the third quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock valued at $8,889,000 after buying an additional 451,135 shares during the period. Finally, Tybourne Capital Management HK Ltd. lifted its position in Bicycle Therapeutics by 72.4% in the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 993,743 shares of the company’s stock valued at $6,907,000 after acquiring an additional 417,400 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.